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ABSTRACT
Introduction Breast and cervical cancer are leading 
causes of morbidity and mortality in women globally, 
with disproportionately high burdens in low- income and 
middle- income countries (LMICs). While the incidence 
of both cancers increases across LMICs, many cases 
continue to go undiagnosed or diagnosed late. The aim 
of this review is to comprehensively map the current 
evidence on the time to breast or cervical cancer diagnosis 
and its associated factors in LMICs.
Methods and analysis This scoping review (ScR) will 
be informed by Arksey and O'Malley’s enhanced ScR 
methodology framework. It will be reported in accordance 
with the Preferred Reporting Items for Systematic reviews 
and Meta- Analyses extension for Scoping Reviews. We 
will conduct a comprehensive search of the following 
electronic databases: MEDLINE (via PubMed), Cochrane 
Library, Scopus and the Cumulative Index to Nursing 
and Allied Health Literature (CINAHL). Two reviewers will 
independently screen all abstracts and full texts using 
predefined inclusion criteria. All publications describing 
the time to diagnosis and its associated factors in the 
contexts of breast or cervical cancer will be considered 
for inclusion. Evidence will be narratively synthesised and 
analysed using a predefined conceptual framework.
Ethics and dissemination As this is a ScR of publicly 
available data, with no primary data collection, it will not 
require ethical approval. Findings will be disseminated 
widely through a peer- reviewed publication and forums 
such as conferences and community engagement 
sessions. This review will provide a user- friendly evidence 
summary for understanding the enormity of diagnostic 
delays and associated factors for breast and cervical 
cancers in LMICs, while helping to inform policy actions 
and implementation of interventions for addressing such 
delays.
INTRODUCTION
Breast and cervical cancer are leading causes 
of morbidity and mortality in women glob-
ally.1 2 The incidence of both cancers and 
their associated morbidity and mortality are 
disproportionately high in low- income and 
middle- income countries (LMICs).2 3 Breast 
cancer is the most common cancer among 
women worldwide, with an age- standardised 
incidence rate (ASIR) of 31 per 100 000 
women in LMICs.4 5 Cervical cancer accounts 
for 16% of the cancer burden in LMICs, with 
an ASIR of 16 per 100 000 women.2 More-
over, the number of new cases and subse-
quent cancer deaths in LMICs are expected 
to grow substantially in the coming decades.6 
This growth has been attributed to popu-
lation growth and increasing exposure to 
behavioural, dietary and environmental risk 
factors; in keeping with the epidemiological 
transition from communicable diseases to 
non- communicable diseases in developing 
countries.1 6
Cancer mortality and survival are influ-
enced by the timeliness of diagnosis and access 
to effective treatment.7–9 If diagnosed early, 
breast and cervical cancers are amenable to 
treatment with curative intent.10 11 Timely 
diagnosis is critical for optimising patients’ 
navigation of the pathway from cancer 
symptom awareness to treatment.12–14 While 
the incidence of cancers increases across 
Strengths and limitations of this study
 ► This scoping review will be conducted in accordance 
with an enhanced evidence synthesis methodol-
ogy and will be reported using standard reporting 
guidelines.
 ► This review will update and fill an existing gap in the 
evidence relating to the nature of the time to diagno-
sis of breast and cervical cancer and associated fac-
tors associated in low- income and middle- income 
countries.
 ► Literature searches will be comprehensive, covering 
both peer- reviewed and relevant grey literature, with 
no language restrictions.
 ► Due to the broad nature of the topic, it is possible 
that some relevant literature may not be identified 
by our search strategy, however comprehensive.
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LMICs, many cases continue to go undiagnosed or diag-
nosed at a late stage when treatment is often less effective 
and more expensive.7 8 15
In LMICs, timely cancer diagnosis is often constrained 
by patient and disease factors, as well as health system 
barriers.16–18 Patient factors include those that are demo-
graphic, psychological and behavioural, in addition to 
those associated with underlying sociocultural barriers to 
early cancer diagnosis such as lay beliefs.16 19 20 Lay beliefs, 
such as perceptions that cancers are divine punishments 
for sin committed, are not uncommon in some commu-
nities in LMICs, as are views that cancers are contagious 
and that they are inevitably fatal.21 22 Likewise, there 
are concerns that cancer treatment or surgery (such as 
mastectomy) may result in deformity and consequent 
divorce or family abandonment.17 23 Furthermore, women 
in LMICs often fail to recognise or misinterpret cancer 
symptoms or wait until symptoms worsen before they seek 
medical attention.24 For instance women usually attribute 
the initial symptoms of cervical cancer to normal bodily 
changes or common illnesses such as sexually transmitted 
diseases.25
Disease factors include those related to the site, size, 
clinical manifestation and growth of tumours.18 Health 
system factors in LMICs include access, policy and service 
delivery barriers. Access barriers may be due to physical or 
geographical inaccessibility to health facilities and those 
associated with healthcare costs and affordability.16 18 20 
Service delivery barriers comprise factors such as inade-
quate diagnostic tools, poor referral systems and insuffi-
cient human resources.6 16 26 Cancer diagnostic services 
in LMICs are often dependent on limited government 
funding, not consistently available or affordable, inequi-
tably distributed and nested in fragmented health systems 
with complicated patient referral.16 20
As a result of these, women in LMICs may be reluctant 
to seek care following their awareness of possible cancer 
symptoms, leading to delays in diagnosis. Consequently, 
a high proportion of patients are diagnosed at advanced 
stage, when treatment is often less effective and more 
expensive.16 19 However, little is known about the extent 
to which these factors influence time to diagnosis, partic-
ularly in LMICs.
The measurement of time to cancer diagnosis is also 
complex. Complicating factors include those related to 
the patients, the clinical manifestation of cancers and 
the validity of diagnostic tools.27 Various methodolog-
ical approaches for assessing time of diagnosis and diag-
nostic intervals exist, while their use in LMICs has grown 
over the years.22 26 28 However, only a minority of these 
tools are theoretically informed and validated.27 Studies 
assessing appraisal intervals (time taken to interpret 
bodily changes/symptoms) and help- seeking intervals 
(time taken to act on those interpretations and seek 
help) commonly use tools that ignore existing models 
of patient behaviour, and are poorly or inadequately 
validated.18 29 To help address these measurement gaps, 
the distinct phases of cancer patients’ pathways from 
symptom awareness to diagnosis and treatment have been 
conceptualised by the Model of Pathways to Treatment 
proposed by Walter, Scott and colleagues.18 29 According 
to the framework, there are five key events in the pathway 
to care: detection of bodily changes; perceived reasons to 
discuss symptoms with a healthcare provider; first consul-
tation with a healthcare provider; diagnosis and start of 
treatment. The framework also identifies four important 
intervals between these phases: the appraisal, help- 
seeking, diagnostic and pre- treatment intervals. These 
events and processes represent particular moments at 
which barriers may exist and delay patients’ access to care 
before or after a cancer diagnosis.7 30 In response to the 
well- recognised need to develop valid tool for measuring 
time to cancer diagnosis, the Aarhus checklist has been 
proposed for guiding the design and reporting of early 
cancer diagnosis studies.30
STUDY RATIONALE
Understanding the time to breast or cervical cancer diag-
nosis and associated factor is important to guide interven-
tions for addressing diagnostic delays in LMICs.11 31 32 In 
2017, the WHO published the WHO guide to cancer early 
diagnosis.33 It provides a standard framework for systemat-
ically addressing barriers that may impede timely cancer 
diagnosis and treatment, which are particularly prevalent 
in LMICs. Addressing these barriers requires a conceptu-
ally sound understanding of the extent of time to diag-
nosis and the nature of the factors associated with such 
barriers.34
This review aims to provide an up to date and compre-
hensive synthesis of the evidence on the time to breast 
or cervical cancer diagnosis and its associated factors in 
LMICs. Due to the possible lead time and length bias 
of cancer screening programmes (including those of 
breast and cervical cancer), this review will focus on early 
diagnosis of symptomatic breast and cervical cancers. Its 
findings will contribute to better understanding of the 
nature and extent of diagnostic timeliness and delays in 
resource- limited settings. In addition, it seeks to provide 
a systematically organised evidence summary for health 
policy makers, cancer programme managers, oncologists 
and other cancer care providers for guiding policy and 
practice decision making. Finally, it will be useful for 
informing the design of further interventions and strate-
gies for addressing breast and cervical cancer diagnostic 
delays in resource- limited settings, while identifying 
opportunities for future research.
METHODS AND ANALYSIS
Conceptual framework
This scoping review (ScR) will use the Model of Path-
ways to Treatment framework proposed by Walter, Scott 
and colleagues18 29 to map the identified evidence on the 
time intervals for breast or cervical cancer diagnosis and 
associated factors. The framework (See figure 1) specifies 
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the essential events, processes and time intervals that 
may occur in the period prior to diagnosis and the start 
of medical treatment and identifies the factors that may 
contribute to the duration of each time interval.
STUDY DESIGN
This ScR is informed by Arksey and O'Malley’s ScR meth-
odology,35 as enhanced by Levac and colleagues.36 The 
enhanced framework involves six stages for undertaking a 
ScR: (1) identifying the research question; (2) identifying 
the relevant studies (defining the inclusion and exclusion 
criteria); (3) searching and selecting the evidence; (4) 
charting the evidence; (5) collating, summarising and 
reporting the evidence and (6) consultation with relevant 
stakeholders.
STEP 1: IDENTIFYING THE RESEARCH QUESTION
The ScR seeks to answer the questions: ‘What is the 
current evidence on the time to breast and cervical cancer 
diagnosis and its associated factors in LMICs?’
Specifically, it will answer the following questions:
1. How is time to breast or cervical diagnosis defined or 
measured?
2. What are the time intervals for breast or cervical can-
cer diagnosis in LMICs?
3. What are the factors associated with time to diagnosis 
for breast and cervical cancers in LMICs?
STEP 2: IDENTIFYING THE RELEVANT STUDIES (DEFINING THE 
INCLUSION AND EXCLUSION CRITERIA)
In line with the research question, the inclusion criteria 
are defined using the using the population, concept 
and contexts (PCC) framework, proposed by Peters and 
colleagues.37 This framework is more appropriate for 
ScRs than the population, intervention, comparator and 
outcome (PICO) framework commonly used for system-
atic reviews, as it allows for the consideration of publica-
tions that may not feature all of the four PICO elements 
(eg, lacking an outcome or comparator/control). 
Eligible population will include women with breast or 
cervical cancer and healthcare providers living in LMIC 
contexts. The concepts of interest for this review are time 
to diagnosis and diagnostic intervals for breast and/or 
cervical cancers. Time to diagnosis will include appraisal, 
help- seeking or diagnostic intervals as defined by model 
of pathways to treatment.18 29
To be considered eligible for inclusion, studies will have 
to fulfil one or more of the following: (1) report- specific 
methods, tools or strategies for measuring time intervals 
in the context of breast and/or cervical cancer diagnoses 
in LMICs; (2) assess the time to diagnosis of breast and/or 
cervical cancers in LMIC settings; (3) evaluate the factors 
associated with diagnostic time intervals among women 
with breast and/or cervical cancers in LMICs. The defini-
tion of LMICs will be based on the World Bank’s current 
classification using per capita gross national income.38 
Multinational literature involving LMIC and non- LMIC 
countries and meeting inclusion criteria will be included, 
except where country- specific information cannot be 
abstracted. Similarly, articles involving multiple cancer 
types will be included, except where the relevant cancer 
type- specific information cannot be abstracted.
Articles focused solely or mainly on theoretical and 
conceptual understanding of timeliness of breast or 
cervical cancer diagnosis without assessing the timeliness 
of diagnosis in specific LMIC contexts will be excluded, as 
will those assessing cancer patient pathways that are not 
related to diagnostic time and intervals. Studies focused 
primarily on screening of asymptomatic individuals will 
also be excluded. Study design eligibility will include 
Figure 1 The model of pathways to treatment.
4 Nnaji CA, et al. BMJ Open 2021;11:e044093. doi:10.1136/bmjopen-2020-044093
Open access 
randomised trials, non- randomised trials and observa-
tional studies, with or without controls. However, inclu-
sion will be limited to primary studies; while systematic, 
ScRs and other forms of aggregated evidence will be 
excluded.
STEP 3: SEARCHING AND SELECTING THE EVIDENCE
The literature search will be guided by the research ques-
tions and the PCC criteria. The search strategy will be 
developed with guidance from a health sciences subject 
librarian and will be applied in accordance with the Peer 
Review of Electronic Search Strategies guidelines.39 The 
search strategy will be pretested prior to the actual search. 
Search terms and free- text words will be combined using 
the Boolean operators ‘AND’ and ‘OR’, such as (breast 
OR cervical OR cervix, cancer OR neoplasm OR malig-
nancy OR tumours) AND (diagnosis OR diagnostic OR 
detection OR discovery) AND (early OR timely OR time 
OR late OR delay). Search terms will include the use of 
controlled descriptors, such as Medical Subject Headings 
(MeSH) terms and Cumulative Index to Nursing and 
Allied Health Literature (CINAHL) headings, and their 
synonyms. In order to restrict search to LMICs, a loca-
tion filter containing all countries currently classified as 
part of LMICs and synonymous geographical, regional 
and economic categorisations will be incorporated. See 
online supplemental appendix for provisional search 
strategy.
A comprehensive literature search will be conducted 
on the following electronic databases: MEDLINE (via 
PubMed), Cochrane Library (including the Cochrane 
Central Register of Controlled Trials (CENTRAL) and 
the Database of Abstracts of Reviews of Effects), Scopus, 
CINAHL and the International Clinical Trials Registry 
Platform. Additionally, relevant grey literature will be 
searched for potentially eligible articles, including the 
publication database of the WHO’s International Agency 
for Research on Cancer, the Cancer Atlas of the Union 
for International Cancer Control and the Global Cancer 
Project Map. A hand search of reference lists of included 
studies will be conducted. For recency, only articles 
published over the last 10 years (from 2010 to date) will 
be considered eligible. No language restrictions will be 
applied, and any potentially eligible article in a language 
other than English will be translated using a web- based 
translation tool.40 The preliminary literature search was 
initiated on 9 November 2020, and completed on 15 
January 2021.
The review process will consist of two levels of screening: 
a title and abstract screening to identify potentially eligible 
publications and review of full texts to select those to be 
included in the review based on predefined inclusion/
exclusion criteria. For the first level of screening, two 
reviewers (CAN and PK) will independently screen the 
titles and abstracts of all retrieved records from the search 
output. Articles that are considered relevant by either 
or both of the reviewers will be included in the full- text 
assessment. Following the removal of duplicates, full texts 
of remaining studies will be retrieved. In the second step, 
the two reviewers will then independently assess the full 
texts to determine if they meet the inclusion/exclusion 
criteria. Any discordance in their eligibility assessment 
will be resolved through consensus between the two 
researchers. Any further disagreements will be resolved 
by a third reviewer (JM).
STEP 4: CHARTING THE EVIDENCE
Two reviewers (CAN and PK) will independently abstract 
and record all relevant data using a standardised data 
abstraction tool, adapted from the framework proposed by 
Carlos and colleagues.41 The tool includes four domains: 
(1) study identification details (article title; journal title; 
authors; country of the study; language; publication year; 
host institution of the study); (2) methodological charac-
teristics (study design; study objective or research ques-
tion or hypothesis; sample characteristics (eg, sample 
size; sex; age, ethnicity; groups and controls; follow- up 
duration; validation of measures; statistical analyses); (3) 
main findings and (4) conclusions. Study eligibility will 
be reverified at the start of/during data extraction.
Where the relevant outcome data in any article are 
unclear or missing, the corresponding author will be 
contacted via email for clarification. Any discrepancies 
in the abstracted data between the two reviewers will be 
resolved by discussion, and if a consensus is not reached, 
a third reviewer (JM) will arbitrate. The first reviewer 
(CAN) will combine the two spreadsheets of abstracted 
data for analysis. PK will double- check the entered data 
for completeness and verify the accuracy of analysis. 
JM and FMW will review analysed data for accuracy and 
consistency with protocol.
STEP 5: COLLATING, SUMMARISING AND REPORTING THE 
EVIDENCE
Findings of the review will be reported using the Preferred 
Reporting Items for Systematic reviews and Meta- Analyses 
extension for Scoping Reviews guidelines.42 Findings will 
be narratively summarised and reported based on themes 
that will emerge from the charted evidence. Where appli-
cable, quantitative evidence will be aggregated using 
summary statistics. Diagnostic phases and intervals will be 
synthesised and reported based on the model of pathways 
to treatment proposed by Walter, Scott and colleagues 
which describes five key events in the pathway to care 
and also identifies the distinct intervals between these 
phases.18 29 The model also allows for the assessment of 
patient- related, healthcare provider and health system- 
related and disease- related factors that could influence 
the intervals.
As the purpose of a ScR is to aggregate evidence and 
present a summary of the evidence rather than to evaluate 
the quality of the individual evidence, this review’s overall 
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assessment of the strength of the synthesised evidence will 
be narrative rather than quantitative.
STEP 6: CONSULTATION WITH STAKEHOLDERS
Stakeholder consultations provide opportunities to 
enable stakeholders to build on the evidence and offer 
additional insights, practical meaning and perspectives 
to the findings of the review.36 Hence, we will engage 
with health policy makers, cancer programme managers, 
researchers, oncologists and other cancer care providers 
to help identify grey literature that may not be obtain-
able from scholarly database searches, as well as providing 
conceptual and practical insights for guiding the inter-
pretation and dissemination of findings.
PATIENT AND PUBLIC INVOLVEMENT
As this is a protocol for a ScR of already existing liter-
ature, and no participant recruitment will take place, 
patients were not directly involved in the development of 
this protocol.
ETHICS AND DISSEMINATION
This will be a ScR of publicly available literature, with 
no primary data collection. Hence, it will not require 
ethical approval. Findings will be disseminated widely 
through peer- reviewed publication and in various media, 
for example, conferences, congresses or symposia. This 
review will provide a user- friendly evidence summary for 
health policy makers, cancer programme managers and 
frontline health workers, for informing further efforts at 
addressing breast and cervical cancer diagnostic delays 
in LMICs, while identifying opportunities for future 
research.
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